このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Gain Therapeutics マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Gene Mack

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	2.1yrs
取締役会の平均在任期間	3.5yrs

経営陣の近況

Recent updates

Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential

May 29

Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential

Jan 12

Gain Therapeutics appoints CEO

Sep 20

Gain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value

Oct 27

Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing

Aug 19

Gain Therapeutics EPS misses by $0.29

May 10

CEO（最高経営責任者

Gene Mack

less than a year

在職期間

Mr. Gene Mack, M.B.A. is Chief Financial Officer of Gain Therapeutics, Inc. from April 8, 2024 & serves as it's Interim CEO since June 25, 2024. Mr. Mack serves as Chief Financial Officer of Imcyse SA sinc...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Khalid Islam	Executive Chairman	7.5yrs	US$99.90k	3.5% $ 986.5k
Gene Mack	CFO & Interim CEO	less than a year	データなし	データなし
Joanne Taylor	Senior Vice President of Research	2.1yrs	データなし	データなし
Terenzio Ignoni	Senior Vice President of Technical Operations	3.1yrs	データなし	データなし
Jonas Hannestad	Chief Medical Officer	less than a year	データなし	データなし

2.1yrs

平均在職期間

経験豊富な経営陣: GANXの経営陣は経験豊富であると考えられます ( 2.1年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Khalid Islam	Executive Chairman	7.5yrs	US$99.90k	3.5% $ 986.5k
Dov Goldstein	Independent Director	3.5yrs	US$86.90k	0% $ 0
Samuel Broder	Member of Scientific Advisory Board	no data	データなし	データなし
Gwen A. Melincoff	Independent Director	3.5yrs	US$69.90k	0% $ 0
Hans Hasler	Independent Director	3.5yrs	US$83.40k	0% $ 0
Eric Richman	Director	4yrs	US$12.50k	1.14% $ 322.0k
Luca Benatti	Chairman of the Scientific Advisory Board	3.5yrs	データなし	データなし
Jeffrey Riley	Independent Director	5.2yrs	US$85.40k	0.12% $ 33.6k
Lorenzo Leoni	Member of Scientific Advisory Board	3.5yrs	データなし	データなし
Claude Nicaise	Independent Director	3.5yrs	US$74.90k	0% $ 0
Michel Vellard	Member of Scientific Advisory Board	5.7yrs	データなし	データなし

3.5yrs

平均在職期間

65.5yo

平均年齢

経験豊富なボード: GANXの取締役会は経験豊富であると考えられます ( 3.4年の平均在任期間)。

Gain Therapeutics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Gain Therapeutics, Inc. Announces CEO Changes

Gain Therapeutics, Inc., Annual General Meeting, Jun 24, 2024

Gain Therapeutics, Inc. Appoints Gene Mack as Chief Financial Officer

Independent Director recently bought US$116k worth of stock

Gain Therapeutics, Inc. Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

Gain Therapeutics, Inc. Announces Xavi Barril Leaves as Chief Technology Officer

Recent updates

Gain Therapeutics, Inc. Announces CEO Changes

Gain Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $10.999898 million.

Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential

Consensus EPS estimates upgraded to US$0.97 loss, revenue downgraded

Gain Therapeutics, Inc., Annual General Meeting, Jun 24, 2024

Consensus revenue estimates fall by 40%

Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287

Gain Therapeutics, Inc. Appoints Gene Mack as Chief Financial Officer

Independent Director recently bought US$116k worth of stock

Gain Therapeutics, Inc. Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

New major risk - Financial position

Gain Therapeutics, Inc. Announces Xavi Barril Leaves as Chief Technology Officer

Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential

Consensus revenue estimates decrease by 11%, EPS upgraded

Gain Therapeutics, Inc. Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

Gain Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $6.65573 million.

Gain Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $6.65573 million.

Gain Therapeutics, Inc. has filed a Follow-on Equity Offering.

Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

Gain Therapeutics Presents New Preclinical Data Demonstrating A Reduction of Plasma Neurodegeneration Biomarker NfL After Administration of Its Drug Candidate GT-02287 in GBA1 Parkinson's Disease Model

Consensus revenue estimates fall by 16%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.62 loss per share (vs US$0.43 loss in 2Q 2022)

Consensus revenue estimates increase by 193%, EPS downgraded

Consensus revenue estimates increase by 17%

Gain Therapeutics, Inc. Announces Executive Changes

Consensus revenue estimates increase by 24%

High number of new and inexperienced directors

Gain Therapeutics, Inc. Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinson's Disease Patient-Derived Dopaminergic Neurons

Gain Therapeutics Announces Chief Executive Officer Changes

Gain Therapeutics appoints CEO

Gain Therapeutics, Inc. Presents New Preclinical Data Demonstrating Potential Disease Modifying Benefits of Its Novel Brain Penetrant Small Molecule Candidate GT-02287 in Two Preclinical Models of Parkinson's Disease

Price target decreased to US$19.25

Consensus forecasts updated

Consensus forecasts updated

Gain Therapeutics, Inc., Annual General Meeting, Jun 16, 2022

Price target decreased to US$22.00

High number of new and inexperienced directors

Price target decreased to US$22.00

Gain Therapeutics Presents Additional Confirmatory Data on its Gaucher Disease Program at the 2022 Glycolipid

Gain Therapeutics Presents Preclinical Data on Its Structurally Targeted Allosteric Regulators in Gba1 Gaucher Disease At the Worldsymposium 2022

Gain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value

Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-Derived Ipsc Study Evaluating Star Compounds as A Treatment for Gaucher and Parkinson’S Disease

Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing

Gain Therapeutics EPS misses by $0.29

Gain Therapeutics, Inc. Presents Positive In Vitro & In Vivo Data on Its Orally Bioavailable Brain Penetrant Star Compounds for the Treatment of GBA1 Parkinson’s Disease & Related a-synucleopathies at the XXVI IAPRD World Congress

Gain Therapeutics, Inc. has completed an IPO in the amount of $40.000004 million.

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24